Advancing Treatment for Fragile X Syndrome & Other Cognitive Disabilities

Ongoing Clinical Trials:

Fragile X Syndrome

Tetra Therapeutics is conducting clinical trials with zatolmilast (BPN14770) to assess efficacy in enhancing cognitive function in males aged 9 to 45 years with Fragile X Syndrome.

Select the links below for additional information and participating locations: 

Expanded Access Policy

How might BPN14770 help Fragile X Syndrome patients?

In Fragile X Syndrome, BPN14770 may help connections in the brain to mature, thereby improving brain function. Dr. Elizabeth Berry-Kravis explains the previous Phase 2 trial in this short video.

We welcome your interest in participating in a clinical trial

For more general information about the progress we’re making in developing therapeutic products that treat brain disorders, follow us on Facebook and LinkedIn.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.